Therefore, it is essential to conduct further follow-up studies to delve deeper into the impact of interleukins (IL-5, IL-7, IL-16, and IL-10) on the two subtypes of breast cancer (HER2-positive and HER2-negative). This evidence concerns the gene IL7 and breast carcinoma.